Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab

In locally advanced non-small cell lung cancer (NSCLC) patients, consolidation therapy with durvalumab (an anti-PD-L1 monoclonal antibody) has proven to significantly increase both progression free and overall survival after chemoradiotherapy. Here, we describe a case of acute pneumonitis during dur...

Descripción completa

Detalles Bibliográficos
Autores principales: Tonk, Erwin H.J., van Lindert, Anne S.R., Verhoeff, Joost J.C., Suijkerbuijk, Karijn P.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738224/
https://www.ncbi.nlm.nih.gov/pubmed/31543778
http://dx.doi.org/10.1159/000502202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738224/
https://www.ncbi.nlm.nih.gov/pubmed/31543778
http://dx.doi.org/10.1159/000502202

Ejemplares similares